Eco Animal Health Group PLC Deferred Share Option Award to Executive Directors
2024年8月29日 - 3:00PM
RNS Regulatory News
RNS Number : 0512C
Eco Animal Health Group PLC
29 August 2024
29 August
2024
ECO Animal Health Group
plc
("ECO" or
the "Company")
Deferred Share Option Awards to
Executive Directors
ECO Animal Health Group plc (AIM: EAH), a
rapidly growing global animal health company with a portfolio of
marketed veterinary products and a maturing proprietary R&D
pipeline, announces that on 28 August 2024
nominal cost share options were granted under the Company's
Deferred Bonus Plan ("DBS") over 143,452 ordinary shares in the
Company (representing approximately 0.21 percent of the Company's
issued share capital) to two Executive Directors listed below.
These awards relate to the deferral of 33% of the annual bonus for
Executive Directors earned in respect of the Company's financial
year ended 31 March 2024.
|
Name
|
Position
|
Number of Deferred Share
Options
|
|
David Hallas
|
Chief Executive Officer
|
82,437
|
|
Chris Wilks
|
Chief Financial Officer
|
61,015
|
As indicated in the Circular to
shareholders dated 4 February 2021, the DBS has been established to
allow the Remuneration Committee to require a significant part of
the annual bonuses paid to Executive Directors to be deferred in
exchange for an award of nominal cost options which vest after 3
years.
-Ends-
For further
information please contact:
|
ECO Animal
Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO)
|
020 8447 8899
|
|
Singer Capital
Markets (Nominated Adviser & Joint Broker)
Phil Davies
Sam Butcher
|
020 7496 3000
|
|
Investec
(Joint Broker)
Gary Clarence
Lydia Zychowska
|
020 7597 5970
|
|
Equity
Development
Hannah Crowe
Matt Evans
|
020 7065 2692
|
|
ICR Consilium
(Financial PR)
Mary-Jane Elliott
Jessica Hodgson
|
020 3709 5700
ecoanimalhealth@consilium-comms.com
|
|
|
About ECO
Animal Health
ECO Animal Health is a world leader in animal
health, developing and marketing branded veterinary pharmaceuticals
globally, with expertise in antibiotics and vaccines for pigs and
poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices
including R&D and manufacturing, we have marketing
authorisations in over 70 countries and employ over 200 people
worldwide.
Our lead product, Aivlosin® is a proprietary,
patented medication which is effective against both respiratory and
intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
PDMR Notification - ECO DBS Deferred Share Option
Awards
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a.
|
Name
|
1. David
Hallas
2. Chris
Wilks
|
|
2.
|
Reason for the notification
|
|
a.
|
Position/status
|
1. Chief Executive
Officer
2. Chief
Financial Officer
|
|
b.
|
Initial notification
/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Eco Animal Health Group Plc
|
|
b.
|
LEI
|
2138009XN9DJ3YP70B55
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the
Financial instrument, type of
instrument
Identification code
|
Options over ordinary shares of 5p
each.
GB0032036807
|
|
b.
|
Nature of the transaction
|
Award of nominal cost share options
under the Company's DBS.
|
|
c.
|
Price(s) and volume(s)
|
Numbers 1 and 2 in the left-hand
column correspond to the relevant PDMR as detailed in boxes 1a and
2a above.
|
Price(s)
|
Volume(s)
|
|
1. 5p
|
82,437
|
|
2. 5p
|
61,015
|
|
|
d.
|
Aggregated information
Aggregated volume
Price
|
n/a
|
|
e.
|
Date of the transaction
|
28 August 2024
|
|
f.
|
Place of the transaction
|
Outside a trading venue.
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHPPMFTMTMTBJI
Eco Animal Health (LSE:EAH)
過去 株価チャート
から 11 2024 まで 12 2024
Eco Animal Health (LSE:EAH)
過去 株価チャート
から 12 2023 まで 12 2024
